Daina Graybosch
Stock Analyst at Leerink Partners
(1.05)
# 2,703
Out of 4,413 analysts
99
Total ratings
34.48%
Success rate
-13.78%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $4.60 | +291.30% | 5 | Jan 31, 2024 | |
| BOLT Bolt Biotherapeutics | Upgrades: Outperform | $4 | $1.12 | +257.14% | 7 | May 12, 2023 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $52.18 | -25.26% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $1.65 | +81.82% | 7 | Feb 24, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $120 → $122 | $128.80 | -5.28% | 15 | Feb 3, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $3.04 | +360.53% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $4.09 | +144.50% | 6 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $5.35 | +1,021.50% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.54 | +254.33% | 9 | Nov 15, 2022 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $15.50 | +145.16% | 2 | Nov 3, 2022 | |
| LVTX LAVA Therapeutics | Maintains: Outperform | $25 → $28 | $2.97 | +842.76% | 5 | Sep 27, 2022 | |
| MOLN Molecular Partners AG | Downgrades: Market Perform | $30 → $8 | $3.87 | +106.72% | 4 | Aug 29, 2022 | |
| BNTX BioNTech SE | Maintains: Outperform | $223 → $224 | $89.95 | +149.03% | 13 | Jul 29, 2022 | |
| NKTX Nkarta | Initiates: Outperform | $30 | $7.49 | +300.53% | 1 | Jul 18, 2022 | |
| ITOS iTeos Therapeutics | Maintains: Outperform | $60 → $59 | $11.78 | +400.85% | 4 | May 13, 2022 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $18 → $17 | $6.02 | +182.39% | 3 | May 11, 2022 | |
| CGEN Compugen | Maintains: Outperform | $16 → $9 | $1.99 | +352.26% | 2 | Feb 25, 2022 |
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $4.60
Upside: +291.30%
Bolt Biotherapeutics
May 12, 2023
Upgrades: Outperform
Price Target: $4
Current: $1.12
Upside: +257.14%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $52.18
Upside: -25.26%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $1.65
Upside: +81.82%
Merck & Co.
Feb 3, 2023
Maintains: Outperform
Price Target: $120 → $122
Current: $128.80
Upside: -5.28%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $3.04
Upside: +360.53%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $4.09
Upside: +144.50%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $5.35
Upside: +1,021.50%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.54
Upside: +254.33%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $15.50
Upside: +145.16%
LAVA Therapeutics
Sep 27, 2022
Maintains: Outperform
Price Target: $25 → $28
Current: $2.97
Upside: +842.76%
Molecular Partners AG
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.87
Upside: +106.72%
BioNTech SE
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $89.95
Upside: +149.03%
Nkarta
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $7.49
Upside: +300.53%
iTeos Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $11.78
Upside: +400.85%
Werewolf Therapeutics
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $6.02
Upside: +182.39%
Compugen
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.99
Upside: +352.26%